LAS VEGAS, July 12, 2018 /PRNewswire/ --
FN Media Group Presents Microcapspeculators.com News Commentary
Many medical companies throughout the world are pinning their hopes for miracle cures on stem cell therapies. Because of the ability of stem cells to differentiate into all cells within the body, they are central to the field of regenerative medicine, which seeks to restore or establish normal healthy functions in patients with serious disorders by regenerating human cells, tissues or organs.I would not reference embryonic stem cells - we use adult stem cells and embryonic cells are a whole other animal with certain aged baggage.
These stem cell companies are innovating for the future: BioRestorative Therapies, Inc. (OTC:BRTX), Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Athersys, Inc. (NASDAQ:ATHX), Vericel Corp (NASDAQ:VCEL), Fate Therapeutics, Inc. (NASDAQ:FATE)
BioRestorative Therapies, Inc. (OTCQB:BRTX)
Market Cap: $11.17M, current share price: $1.70
BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes.
BRTX-100 is a novel product to treat damaged, degenerating discs, and is anticipated to be safer, cheaper, and more effective upon a single treatment. Specifically, BRTX-100 is an autologous stem cell product that uses your own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process.
To target obesity and metabolic disorders, they developed their ThermoStem® program that uses brown adipose-derived ("brown fat") stem cells to generate new brown fat tissue. BioRestorative Therapies was one of the first companies to identify and publish data about this novel stem cell population. This population of fat is known to burn, rather than store, energy. Elevated levels of brown fat have been demonstrated to increase metabolism and facilitate weight loss. Initial preclinical research indicates that increased amounts of activated brown fat in the body may be responsible for additional caloric burning, as well as reduced glucose and lipid levels.
A month ago, Defined Health (a pharma and targeted scientific consulting firm) conducted an independent review of BRTX-100, which is BioRestorative Therapies, Inc. lead cell therapy candidate designed to treat chronic Lumbar Disc Disease (cLDD). As the report concluded, the Key Opinion Leaders (KOLs) reacted positively to the value proposition of BRTX-100 and scientists are optimistic that the clinical data presented to date is likely to be mirrored in future clinical investigations. If BRTX-100 were to be granted FDA approval, KOLs anticipate that it would be integrated into the standard of care for eligible cLDD patients.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO)
Market Cap: $1.59B, current share price: $15.70
Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS.
Athersys, Inc. (NASDAQ:ATHX)
Market Cap: $274.53M, current share price: $1.99
Athersys, Inc., is a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase II study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase II clinical study for treating patients with acute myocardial infarction; and, which is in Phase I/II clinical study for treating patients with acute respiratory distress syndrome, as well as that has completed Phase I clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need.
Vericel Corp (NASDAQ:VCEL)
Market Cap: $420.07M, current share price: $9.90
Vericel Corporation, is a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
Fate Therapeutics, Inc. (NASDAQ:FATE)
Market Cap: $634.30M, current share price: $12.00
Fate Therapeutics, Inc.,is a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases.
DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and one thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article's distribution.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
Contact Information:
Company Name: Microcap Speculators
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Media Contact
FN Media Group LLC
e-mail: editor@financialnewsmedia.com
+1-(954)345-0611
SOURCE Microcapspeculators.com
Share this article